STEMCELL-TECHNOLOGIES
29.2.2024 22:44:31 CET | Business Wire | Press release
STEMCELL Technologies is pleased to announce the acquisition of substantially all assets of SQZ Biotechnologies Company (SQZ)—a Massachusetts-based biotech known for its game-changing method of introducing a variety of therapeutic cargo into cells by squeezing them (mechanoporation) rather than using electricity (electroporation).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240229339343/en/
STEMCELL Technologies is pleased to announce the acquisition of substantially all assets of SQZ Biotechnologies Company (SQZ)—a Massachusetts-based biotech known for its game-changing method of introducing a variety of therapeutic cargo into cells by squeezing them (mechanoporation) rather than using electricity (electroporation). This transaction, which was approved by SQZ shareholders on February 29, 2024, marks another significant milestone for STEMCELL, Canada’s largest biotechnology company. (Photo: Business Wire)
This transaction, which was approved by SQZ shareholders today, marks another significant milestone for STEMCELL, Canada’s largest biotechnology company.
“This exciting acquisition means that STEMCELL’s own instruments will have the potential to be used in the delivery of cell therapies to cure diseases, like cancer,” said Dr. Allen Eaves, President and CEO, STEMCELL. “This transaction is an important achievement for STEMCELL and a win for Canada’s economy and life sciences sector as it will support the development of innovative cell therapies.”
This is STEMCELL’s second acquisition in the biotechnology sector this year. In January 2024, STEMCELL purchased Propagenix Inc., a Maryland-based biotechnology company focused on developing technologies to enable new approaches in regenerative medicine.
With the approval of the SQZ transaction, STEMCELL has acquired substantially all of SQZ’s assets including its entire portfolio of over 400 patents and trademarks, other intellectual property such as copyrights and trade secrets, proprietary equipment, and its head license with the Massachusetts Institute of Technology.
“Since our inception, SQZ’s vision has been to transform patient outcomes by helping to make life-changing cell therapies widely and rapidly accessible, and we are confident that STEMCELL can drive this important ambition toward a global reality,” said Dr. Howard Bernstein, Interim CEO, SQZ Biotechnologies.
In 2020, STEMCELL exclusively licensed the rights to SQZ’s patent portfolio to develop and commercialize the CellPore™ Transfection System and associated CellPore™ Transfection Kits in the research use market. With this new agreement, STEMCELL will be able to exclusively commercialize these products for use in all markets, including clinical applications.
“Over our 30-year history, STEMCELL has proudly developed the products required for scientific research around the world, and now with SQZ’s technology and proprietary expertise, we are poised to increase our offering even further into the clinical space and ultimately help patients everywhere,” said Dr. Eaves.
About STEMCELL Technologies
STEMCELL Technologies supports life sciences research with more than 2,500 specialized reagents, tools, and services. STEMCELL offers high-quality cell culture media, cell separation technologies, instruments, accessory products, educational resources, and contract assay services that are used by scientists performing stem cell, immunology, cancer, regenerative medicine, and cellular therapy research globally.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240229339343/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ares Management Prices European Direct Lending CLO II at Over €300 Million19.2.2026 18:25:00 CET | Press release
Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today the pricing of its second European Direct Lending Collateralized Loan Obligation, Ares European Direct Lending CLO II (“EDL CLO II”), at over €300 million. Consistent with the underlying composition of its predecessor, EDL CLO II is a diversified CLO comprised entirely of directly originated and actively managed loans issued by over 70 middle-market companies predominantly based in Western Europe and primarily operating in resilient industries. The instrument is weighted towards senior-secured floating rate loans and will be rated by S&P and KBRA. Ares believes EDL CLO II is among the first multi-currency middle-market CLOs in Europe. “We are pleased to successfully price our second European Direct Lending CLO in less than 12 months as we continue building on our nearly 20 years of corporate direct lending experience in Europe,” said Michael Dennis, Partner and Co-Head of
Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis19.2.2026 18:00:00 CET | Press release
Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate response to either conventional treatment options or tumor necrosis factor (TNF) antagonists, found nearly half (47.3%) of randomized patients achieved primary endpoint of clinical remission at 54 weeksVedolizumab’s safety profile was generally consistent with its known safety profile in adultsResults were presented at the 21st Congress of the European Crohn’s and Colitis Organisation (ECCO) Takeda (TSE:4502/NYSE:TAK) today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO® (vedolizumab) can offer the possibility of clinical remission for patients ages 2 and older with moderately to severely active ulcerative colitis (UC), a chronic inflammatory disease of the gastrointestinal tract and one of the two most common types of inflammatory bowel disease.1,2 The results, presented at the 21st Congress of the European Crohn’
Andersen Consulting udvider sine kompetencer inden for data og analyse med Insight Consulting19.2.2026 17:06:00 CET | Pressemeddelelse
Andersen Consulting styrker sin platform gennem en samarbejdsaftale med Insight Consulting, der er en førende rådgivningsvirksomhed inden for data og digital strategi med tilstedeværelse i Sydafrika, Mozambique og Storbritannien. Insight Consulting tilbyder end-to-end-ydelser på tværs af den digitale værdikæde, herunder digital strategi, digital kompetenceudvikling, enterprise AI, skræddersyet softwareudvikling, dataintegration, analyse samt planlægning og forecasting. Virksomhedens tværfaglige teams kombinerer ekspertise inden for mennesker, teknologi og processer og sikrer, at effektiv forandringsledelse omfatter alle tre elementer. Virksomheden arbejder på tværs af brancher som detailhandel, logistik, oplevelsesbranchen, finans, fremstillingsindustrien, rejsebranchen, landbrug, transport og sundhed. "Samarbejdet med Andersen Consulting giver os adgang til et bredere globalt fodaftryk og avancerede metoder, samtidig med at vi kan bidrage med vores regionale indsigt og ekspertise inde
Visa Renews Partnership Across Red Bull Formula One Teams19.2.2026 15:00:00 CET | Press release
Long‑term renewal deepens Visa’s presence across Red Bull F1 Teams with enhanced branding, fan access and client experiences Renewed partnership to expand support of Oracle Red Bull Racing and Visa Cash App Racing Bulls Visa (NYSE: V) today announced a multi‑year renewal and expansion of its global partnership with Red Bull F1 Team’s Oracle Red Bull Racing and Visa Cash App Racing Bulls. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219542270/en/ Building on the groundbreaking partnership launched in 2024, the renewed agreement reinforces Visa’s commitment to one of the world’s fastest‑growing sports, while introducing significant new branding rights, enhanced hospitality assets and immersive experiential opportunities across both teams. Visa will also continue as a Title Partner of both Visa Cash App Racing Bulls Formula One Team and its F1 Academy Programme, further strengthening Visa’s presence on and off the grid. “T
Project B Taps Fashion Industry Veteran William Kim as Chief Lifestyle Officer19.2.2026 15:00:00 CET | Press release
Global basketball platform merges elite sport with fashion, design, and culture Project B, an elite global women’s and men’s basketball grand prix built for a new generation of athletes and fans, today announced the appointment of William Kim as Chief Lifestyle Officer. In this strategic role, Kim will lead Project B’s premium lifestyle business across merchandise, brand collaborations, and cultural partnerships as Project B expands across Europe, Asia, and the Americas to create the most premium cultural platform in global sport. “We are building a model designed for 2030 and beyond,” said Kim. “It starts with creating exceptional products. We’re sourcing the highest quality natural fibers for every moment in an athlete’s day and offering those same collections to the broader fan community. From design to supply chain to final consumer experience, we are operating with the same discipline and control as a luxury house, overseeing product, distribution, and brand experience holisticall
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom